Birmingham Capital Management Co. Inc. AL lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,907 shares of the company's stock after selling 1,669 shares during the period. Johnson & Johnson comprises 2.2% of Birmingham Capital Management Co. Inc. AL's investment portfolio, making the stock its 13th biggest position. Birmingham Capital Management Co. Inc. AL's holdings in Johnson & Johnson were worth $5,916,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in JNJ. Dogwood Wealth Management LLC raised its stake in Johnson & Johnson by 13.9% during the 4th quarter. Dogwood Wealth Management LLC now owns 4,224 shares of the company's stock valued at $611,000 after acquiring an additional 514 shares during the last quarter. American Investment Services Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $1,462,000. BridgePort Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $412,000. Park Square Financial Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $331,000. Finally, Total Wealth Planning & Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter valued at $628,000. Hedge funds and other institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ traded up $1.49 during mid-day trading on Friday, hitting $155.07. The company had a trading volume of 4,314,565 shares, compared to its average volume of 7,933,540. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $373.11 billion, a price-to-earnings ratio of 23.32, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm's 50 day simple moving average is $154.43 and its two-hundred day simple moving average is $153.63.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio is presently 57.84%.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Barclays reduced their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $170.88.
Read Our Latest Stock Analysis on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
